Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling

Swati Kushal^{a,1}, Brooke Bullock Lao^{b,1}, Laura K. Henchey^b, Ramin Dubey^a, Hanah Mesallati^a, Nathaniel J. Traaseth^b, Bogdan Z. Olenyuk^{a,2}, and Paramjit S. Arora^{b,2}

^aDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089; and ^bDepartment of Chemistry, New York University, New York, NY 10003

Edited* by Peter B. Dervan, California Institute of Technology, Pasadena, CA, and approved August 16, 2013 (received for review July 2, 2013)

Selective blockade of gene expression by designed small molecules is a fundamental challenge at the interface of chemistry, biology, and medicine. Transcription factors have been among the most elusive targets in genetics and drug discovery, but the fields of chemical biology and genetics have evolved to a point where this task can be addressed. Herein we report the design, synthesis, and in vivo efficacy evaluation of a protein domain mimetic targeting the interaction of the p300/CBP coactivator with the transcription factor hypoxia-inducible factor-1 α . Our results indicate that disrupting this interaction results in a rapid down-regulation of hypoxia-inducible genes critical for cancer progression. The observed effects were compound-specific and dose-dependent. Gene expression profiling with oligonucleotide microarrays revealed effective inhibition of hypoxia-inducible genes with relatively minimal perturbation of nontargeted signaling pathways. We observed remarkable efficacy of the compound HBS 1 in suppressing tumor growth in the fully established murine xenograft models of renal cell carcinoma of the clear cell type. Our results suggest that rationally designed synthetic mimics of protein subdomains that target the transcription factor–coactivator interfaces represent a unique approach for in vivo modulation of oncogenic signaling and arresting tumor growth.

helix mimetics | synthetic inhibitors of transcription | rational design | hydrogen bond surrogate helices

Transcription factors are among the most challenging but attractive targets for drug discovery (1, 2). High-resolution structures of transcription factors in complex with protein partners offer a foundation for rational drug design strategies (3–5). Although many transcription factors exhibit significant intrinsic disorder (6), their complexes with coactivator proteins often feature discrete protein secondary structures, such as α -helices, that contribute significantly to binding and may be used as templates for rational drug design (7, 8). This paper describes design of a stabilized peptide α -helix that can modulate transcription of hypoxia-inducible genes by interfering with interactions of the C-terminal activation domain (C-TAD) of hypoxia-inducible factor-1 α (HIF-1 α) and the cysteine–histidine rich 1 (CH1) domain of the coactivators p300 or CREB-binding protein (CBP; Fig. 1) (9–12). We have shown that an optimized mimic of HIF-1 α C-TAD, HBS 1, a high-affinity ligand of CH1, can down-regulate target genes under hypoxic conditions without affecting the endogenous levels of HIF-1 α . HBS 1 does not adversely affect cell growth at high concentrations, which suggests that the compound is generally nontoxic to normoxic cells. This constrained α -helix retains significant activity in mouse plasma compared with its unconstrained peptide analog (peptide 3), highlighting the ability of stabilized helices to evade serum proteases. We compared the genome-wide effects of HIF-1 α C-TAD mimic 1 and a negative control (HBS 2) using gene expression profiling. The results show that HBS 1 modulates expression of a select set of genes, many of which are of direct relevance to the predicted pathways. Last, the ability of HBS 1 to control tumor progression in a mouse tumor xenograft model was examined. We

find that the synthetic helix provides rapid and effective regression of tumor growth. These results support the hypothesis that functional mimics of protein subdomains that mediate interactions between partner proteins offer an attractive strategy for inhibitor design (13, 14). Such rationally designed molecules, whose cellular targets and function may be envisioned from structures of parent complexes, could offer specific tools to probe cellular signaling networks in a predictable manner.

Results

Design and Synthesis of Stabilized α -Helices. HIF-1 α forms a heterodimer with its β -subunit, aryl hydrocarbon receptor nuclear translocator (ARNT), to recognize hypoxia response element (HRE) and up-regulate expression of hypoxia-inducible genes, which are important contributors to tumor progression (11, 12, 15, 16). Pyrrole–imidazole polyamides, which are programmable DNA-binding small molecules (17), have been shown to regulate transcription of hypoxia-inducible genes by binding to the HRE (18, 19). Initiation of HIF-mediated transcription also requires complex formation between the CH1 domain of the coactivator protein p300 (or the homologous CBP) and the C-TAD_{786–826} of HIF-1 α (Fig. 1A) (20, 21). This transcription factor–coactivator interaction represents an alternative target for controlling hypoxia signaling. Structural studies provide a molecular basis for this interaction and identify two short α -helical domains, α A and

Significance

Protein–protein interactions are attractive targets for interfering with processes leading to disease states. Proteins often use folded domains or secondary structures to contact partner proteins. Synthetic molecules that mimic these domains could disrupt protein–protein contacts, thereby inhibiting formation of multiprotein complexes. This article describes protein domain mimetics (PDMs) that modulate interactions between two proteins that control expression of a multitude of genes under hypoxic environments, such as those found inside tumors. The low-oxygen conditions promote angiogenesis—process of formation of new blood vessels—that together with invasion and altered energy metabolism facilitates tumor growth. We find that the PDMs can control expression of target hypoxia-inducible genes in cell culture and reduce tumor burden in mice.

Author contributions: B.Z.O. and P.S.A. designed research; S.K., B.B.L., L.K.H., R.D., H.M., and N.J.T. performed research; B.Z.O. and P.S.A. analyzed data; and B.Z.O. and P.S.A. wrote the paper.

The authors declare no conflict of interest.

*This Direct Submission article had a prearranged editor.

Data deposition: The gene expression profiling data reported in this manuscript have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE48002).

¹S.K. and B.B.L. contributed equally to this work.

²To whom correspondence may be addressed. E-mail: arora@nyu.edu or bogdan@usc.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1312473110/-DCSupplemental.

Fig. 3. HBS 1 targets p300-CH1 with high affinity and inhibits its binding to HIF-1 α C-TAD_{786–826}. (A) The affinity of **1–3** and HIF-1 α C-TAD_{786–826} for CH1 domain was determined by tryptophan fluorescence spectroscopy. (B) Molecular model that depicts the results of a ¹H-¹⁵N HSQC NMR titration experiment. The p300-CH1 residues undergoing chemical shift perturbations upon addition of HBS **1** are color-mapped, matching the magnitude of the chemical shift changes. HIF-1 α helix B is shown in gold. The model was refined from the NMR structure of the HIF-1 α /CH1 complex (PDB ID code 1L8C). (C) Results of fluorescence anisotropy experiments, showing the ability of HBS **1** to inhibit CH1-^{Flu}HIF C-TAD_{786–826} complex formation.

these conditions. The binding affinity of HIF-1 α C-TAD to CH1 in this assay is consistent with that obtained from a fluorescence polarization assay using fluorescein-labeled HIF-1 α C-TAD (*SI Appendix, Fig. S6*) and those reported in the literature with isothermal titration microcalorimetry (21). The designed specificity control, HBS **2**, targets CH1 with fourfold weaker binding affinity ($K_d = 2,820 \pm 140$ nM), supporting the computational predictions. Peptide **3** is an unconstrained analog of HBS **1** and binds CH1 domain with a K_d of $6,060 \pm 320$ nM. The results indicate that stabilization of the peptide conformation offers a ninefold increase in binding affinity.

To further characterize the interaction of HBS **1** with the CH1 domain, we performed ^1H - ^{15}N HSQC NMR titration experiments with uniformly ^{15}N -labeled CH1. Addition of HBS **1** to 69 μM CH1 in CH1:HBS **1** ratios of 1:1, 1:3, 1:5, and 1:10 resulted in a concentration-dependent shift in resonances of several CH1 residues (Fig. 3B and *SI Appendix, Fig. S7*). Specifically, addition of HBS **1** leads to shifts in resonances of residues corresponding to the cleft into which the αB helix of HIF binds. This cleft includes Trp403, and chemical shift perturbations observed for this residue support the results of the fluorescence titration experiments. The CH1 domain binds to numerous proteins and has been termed a scaffold for protein folding (20, 31). Earlier NMR studies have suggested that Zn^{2+} -bound CH1 has a relatively rigid structure (30), although evidence of plasticity in CH1 has also been discussed (20, 29). Our HSQC titration experiment with HBS **1** supports the view that CH1 has a stable conformation that does not reorganize substantially, at least upon binding of small ligands. Titration of HBS **1** to zinc-bound CH1 led to

a relatively large shift in the side-chain indole NH of W403 compared with the backbone amide proton of this residue, suggesting that side-chain repacking governs binding of these partners (Fig. 3B and *SI Appendix, Fig. S7*) (30).

HBS 1 Disrupts the HIF-1 α /p300-CH1 Complex in Vitro. A fluorescence polarization assay was used to evaluate the ability of HBS 1 to inhibit the binding of fluorescein-labeled HIF-1 α C-TAD_{786–826} domain to p300-CH1 (32, 33). Addition of 1 to the preformed protein complex provided a concentration-dependent decrease in fluorescence polarization, with an inhibitory constant, $K_i = 3.5 \pm 1.2$ μ M (Fig. 3C). Titration of HBS 2 or peptide 3 did not lead to reproducible inhibition of the complex, as expected from their weaker affinity for CH1 domain.

HBS 1 Down-Regulates Hypoxia-Inducible Gene Expression and VEGF Protein Levels in Hypoxic Cells. Based on the confirmed ability of HBS 1 to bind purified p300-CH1 and disrupt CH1/HIF-1 α C-TAD₇₈₆₋₈₂₆ complex formation, we set out to evaluate its potential to down-regulate the hypoxia-inducible promoter activity in a luciferase-based reporter gene system. A construct containing five tandem repeats of the HRE consensus sequence found in the *VEGF* promoter (TACGTGGG), cloned upstream of the human CMV minimal promoter was used to drive expression of firefly luciferase (34). This construct was stably transfected into a triple-negative breast cancer cell MDA-MB-231 that does not express estrogen or progesterone receptors or exhibit human epidermal growth factor receptor 2/Neu (Her2/Neu) amplification. The cells were subsequently treated with the peptides; hypoxia was mimicked by placing cells into a GasPak EZ pouch. Under these conditions, treatment with HBS 1 at a concentration of 50 μ M reduced luciferase expression by 25% (*SI Appendix, Fig. S8*). At the same concentrations, specificity control HBS 2 and unconstrained peptide 3 were found to be less effective. Despite the moderate extent of inhibition of the promoter activity, we were encouraged by these results because MDA-MB-231 cells are aggressive and under hypoxia conditions exhibit confluence-dependent resistance to some anticancer drugs (35). Our luciferase reporter assays suggest that treatment with HBS 1 results in a statistically significant down-regulation of HIF-1 α inducible transcription in this cell line.

To exclude the possibility that the observed down-regulation in the expression of hypoxia-inducible genes was due to a change in the levels of HIF1 α protein itself, we performed a Western blot analysis of HIF-1 α in hypoxic cells treated with HBS 1. HIF-1 α protein was not detectable under normoxia, but is strongly induced under hypoxia mimetic conditions. As expected, the levels of induced HIF-1 α protein were unaffected by the treatment with HBS 1 (*SI Appendix, Fig. S9*).

The ability of HBS **1** and **2** to inhibit hypoxia-induced transcription of target genes (*VEGFA*, *SLC2A1/GLUT-1*, and *LOX*) was evaluated using real-time quantitative RT-PCR (qRT-PCR) assays (*SI Appendix*). The data from qRT-PCR experiments are presented in Fig. 4. HBS **1** reduced expression levels of *VEGF* by 50% at 10 μ M and greater than 60% at 50 μ M, showing marked dose dependence. In contrast, HBS **2** reduced expression levels of this gene by only 10% at 50 μ M, and peptide **3** was completely ineffective even at 50- μ M concentration (Fig. 4A). Next, we determined if this inhibition could be observed for other therapeutically relevant hypoxia-inducible genes. We examined the expression of the *SLC2A1* (*GLUT1*) gene (36), one of the markers of glycolysis in tumors, and *LOX* (37), the hypoxia-inducible gene that has been shown to promote metastasis. In HeLa cells under hypoxia conditions, HBS **1** showed dose-dependent inhibition of *SLC2A1* by 50–60%, comparable to that of *VEGF* gene in the same cell line (Fig. 4B). Similarly, HBS **1** significantly down-regulated levels of expression of the *LOX* gene in a dose-dependent manner (55% and 70%, respectively, Fig. 4C); HBS **2** showed no activity in these assays, whereas peptide **3** had reduced activity of 25%. To rule out the possibility that the compounds are only efficacious under deferoxamine

Fig. 5. Results from gene expression profiling obtained with Affymetrix Human Gene ST 1.0 arrays. (A) Hierarchical agglomerative clustering of 368 transcripts induced or repressed twofold or more (one-way ANOVA, $P < 0.05$) by 300 μ M DFO under the three specified conditions: –, no treatment; 1, HBS 1 (50 μ M); 2, HBS 2 (50 μ M). Clustering was based on a Pearson-centered correlation of intensity ratios for each treatment compared with DFO-induced cells (controls) using average linkage as a distance. Of this DFO-induced set, 92 were inhibited and 30 were induced by HBS 1, whereas 81 were inhibited and 70 induced by HBS 2 ($|\text{fold-change}| \geq 1.1$, $P < 0.05$). (B) Clustering of expression changes of the 45 transcripts induced or repressed fourfold or more ($P < 0.05$) by 300 μ M DFO or by the treatments under the designated treatment conditions. Clustering parameters were the same as in A. (C) Venn diagrams representing transcripts down- and up-regulated ($|\text{fold-change}| \geq 1.1$, $P < 0.05$) by HBS 1 and HBS 2. Numbers inside the intersections represent DFO-induced transcripts affected by both treatments.

possibility that treatment resulted in a reduction of the size of the main tumor but concurrently resulted in an elevated rate of metastasis, as reported with some anti-VEGF therapeutics (42), the animals were injected with IR-783, a near-infrared contrast agent that targets tumors, circulating tumor cells, and metastases (43), and imaged from both sides using a small animal imager. The images show no detectable near-infrared (NIR) signal within the lymph nodes, brain, or other organs, and significantly reduced signal from the main tumor (Fig. 6C).

Discussion

Synthetic inhibitors that block the transactivation domains of transcription factors from contacting their cognate coactivators (3, 44–46), and programmable small molecules that sequence-specifically inhibit DNA–transcription factor interactions, provide powerful strategies for regulating gene expression (17, 47, 48). The blockade of transcription factor interactions can be especially attractive in targeting cellular pathways that promote oncogenic transformation and typically involve a large number of signaling proteins that ultimately converge on a much smaller set of oncogenic transcription factors (2). Given that both CBP and p300 regulate multiple signaling pathways, they provide an

intriguing opportunity for an effective modulation of the expression of genes involved in cancer progression and metastasis (31). Our design strategy involves judicious mimicry of transcription factor fragments that contact p300/CBP to rationally develop artificial regulators of transcription (4, 5).

Our results indicate that synthetic helices that mimic protein subdomains bind their p300/CBP target with high affinity and disrupt the HIF-1 α C-TAD–p300/CBP complex in vitro. Importantly, the designed compounds bound the target protein in a predictable manner; the single residue mutant HBS 2 shows an expected weaker affinity for CH1 compared with HBS 1. The CH1 binding site for HBS 1 was confirmed by NMR HSQC titration experiments. As anticipated based on fluorescence experiments, HBS 1 causes a concentration-dependent chemical perturbation shift for the side chain ϵ -NH of Trp403. This result supports our design principle that a locked helix can occupy the binding clefts of individual protein α -helices (3, 25). The in vitro assays showed significant reduction in promoter activity and effective down-regulation of the expression of HIF-1 α -inducible genes responsible for promoting angiogenesis, invasion, and glycolysis. In addition, the HBS 1-mediated transcriptional blockade of *VEGF* correlates with decreased levels of its secreted protein product, suggesting that compensatory cellular stress-response mechanisms, such as internal ribosome entry sites or mechanisms enhancing protein translation, do not affect the observed down-regulation in expression. Therefore, reducing the cellular mRNA levels of HIF-1 α target genes with HBS 1 could be an effective means of attenuating hypoxia-inducible signaling in tumors.

Comparative analysis of the genome-wide effects of the HBS 1 and 2 provided additional insights into the ability of the compounds to disrupt transcriptional activity of hypoxia-inducible genes. Despite the similarity in structures, these compounds have

Fig. 6. HBS 1 suppresses tumor growth in mouse xenograft models. (A) Box-and-whisker diagram of tumor volumes measured throughout the study with boxes representing the upper and lower quartiles and median and error bars showing maximum and minimum volumes. Tumors from mice treated with HBS 1 were smaller (median volume: 138 mm³) than those of control mice (median: 293 mm³). (B) Results of the weight measurements of control and HBS 1-treated mice throughout the entire duration of the experiments, showing the absence of toxicity-related weight loss. (C) HBS 1 lowers overall tumor burden in mice. Images of mice injected with the tumor-accumulating NIR contrast agent. Mice from the HBS 1-treated group show significantly lower intensity of the NIR signal compared with the control group. The color bar indicates the NIR radiant efficiency (photons s⁻¹ cm⁻² sr⁻¹ per μ W cm⁻²) $\times 10^{10}$.

a very different impact on the level of expression of hypoxia-inducible genes and show distinct genome-wide effects. Treatment with **1** affects 122 genes (less than 0.5% of the entire transcriptome) at a fixed 1.1-fold threshold, with 92 hypoxia-inducible genes being down-regulated. Despite the fact that HBS **2** has a similar genome-wide impact at the same threshold, it does not affect a majority of hypoxia-inducible genes. Because many biological responses are threshold based, the observed decrease in transcriptional activity of primary hypoxia-inducible genes could have pronounced downstream effects on the levels of protein products of hypoxia-inducible transcription.

To assess the *in vivo* potential of HBS **1**, murine tumor xenografts derived from the RCC of the clear cell type were treated with the compound. After five injections of HBS **1**, the median tumor volume was reduced by 53% in the treated group. Importantly, the HBS **1** treatment did not cause measurable changes in animal body weight or other signs of toxicity in tumor-bearing animals, or increase the metastasis rate.

Taken together, the results reported herein support the hypothesis that designed protein domain mimetics can provide valuable tools for probing the mechanisms of transcription. Because the p300/CBP pleiotropic coactivator system interacts with diverse transcription factors, it represents an excellent model system to assess the specificity of designed synthetic ligands in

gene regulation. Future designs will address the possibility of targeting a desired region of a general coactivator as a means of selectively modulating genes under the control of a specific group of transcription factors. The strategy described herein provides a foundation for the development of next-generation genomic tools and, potentially, transcription-based therapies.

Methods

Synthesis and characterization of HBS **1** and **2**, and peptide **3** can be found in *SI Appendix*. Detailed protocols for cloning and expression of the p300-CH1-GST protein, binding assays, cell viability assays, and luciferase expression assays are also included. Western blot analysis of HIF-1 α levels, VEGF ELISAs, gene expression profiling, and *in vivo* efficacy are described in *SI Appendix*.

ACKNOWLEDGMENTS. The authors thank Maria Yamout (Wright group, The Scripps Research Institute) for advice on p300 expression; Jian-Ching Ren of the University of Southern California for help with plasma stability assays; and Daniela Buccella at New York University (NYU) for the use of the spectrofluorometer. Financial support for this work was provided by US National Science Foundation CAREER Award CHE-1161644 (to B.Z.O.) and National Institutes of Health Grant R01GM073943 (to P.S.A.). The microarray analysis was performed at the Genome Technology Center, NYU School of Medicine, partially supported by NYU Cancer Center Support Grant 5P30CA16087-33.

- Ptashe M, Gann A (2002) *Genes and Signals* (Cold Spring Harbor Lab Press, Cold Spring Harbor, NY).
- Darnell JE, Jr. (2002) Transcription factors as targets for cancer therapy. *Nat Rev Cancer* 2(10):740–749.
- Moellering RE, et al. (2009) Direct inhibition of the NOTCH transcription factor complex. *Nature* 462(7270):182–188.
- Rutledge SE, Volkman HM, Schepartz A (2003) Molecular recognition of protein surfaces: High affinity ligands for the CBP KIX domain. *J Am Chem Soc* 125(47):14336–14347.
- Buhrlage SJ, et al. (2009) Amphipathic small molecules mimic the binding mode and function of endogenous transcription factors. *ACS Chem Biol* 4(5):335–344.
- Liu J, et al. (2006) Intrinsic disorder in transcription factors. *Biochemistry* 45(22):6873–6888.
- Bullock BN, Jochim AL, Arora PS (2011) Assessing helical protein interfaces for inhibitor design. *J Am Chem Soc* 133(36):14220–14223.
- Jochim AL, Arora PS (2010) Systematic analysis of helical protein interfaces reveals targets for synthetic inhibitors. *ACS Chem Biol* 5(10):919–923.
- Henchev LK, et al. (2010) Inhibition of hypoxia inducible factor 1-transcription coactivator interaction by a hydrogen bond surrogate alpha-helix. *J Am Chem Soc* 132(3):941–943.
- Fraisl P, Mazzone M, Schmidt T, Carmeliet P (2009) Regulation of angiogenesis by oxygen and metabolism. *Dev Cell* 16(2):167–179.
- Hirota K, Semenza GL (2006) Regulation of angiogenesis by hypoxia-inducible factor 1. *Crit Rev Oncol Hematol* 59(1):15–26.
- Semenza GL (2003) Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* 3(10):721–732.
- Azzarito V, Long K, Murphy NS, Wilson AJ (2013) Inhibition of α -helix-mediated protein-protein interactions using designed molecules. *Nat Chem* 5(3):161–173.
- Wells JA, McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. *Nature* 450(7172):1001–1009.
- O'Rourke JF, Pugh CW, Bartlett SM, Ratcliffe PJ (1996) Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1. *Eur J Biochem* 241(2):403–410.
- Ivan M, et al. (2001) HIF1 α targeted for VHL-mediated destruction by proline hydroxylation: Implications for O₂ sensing. *Science* 292(5516):464–468.
- Dervan PB, Edelson BS (2003) Recognition of the DNA minor groove by pyrrole-imidazole polyamides. *Curr Opin Struct Biol* 13(3):284–299.
- Nickols NG, Jacobs CS, Farkas ME, Dervan PB (2007) Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. *ACS Chem Biol* 2(8):561–571.
- Olenyuk BZ, et al. (2004) Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. *Proc Natl Acad Sci USA* 101(48):16768–16773.
- Freedman SJ, et al. (2002) Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 α . *Proc Natl Acad Sci USA* 99(8):5367–5372.
- Dames SA, Martinez-Yamout M, De Guzman RN, Dyson HJ, Wright PE (2002) Structural basis for HIF-1 α /CBP recognition in the cellular hypoxic response. *Proc Natl Acad Sci USA* 99(8):5271–5276.
- Gu J, Milligan J, Huang LE (2001) Molecular mechanism of hypoxia-inducible factor 1 α -p300 interaction. A leucine-rich interface regulated by a single cysteine. *J Biol Chem* 276(5):3550–3554.
- Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML (2002) Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. *Science* 295(5556):858–861.
- Patgiri A, Jochim AL, Arora PS (2008) A hydrogen bond surrogate approach for stabilization of short peptide sequences in alpha-helical conformation. *Acc Chem Res* 41(10):1289–1300.
- Patgiri A, Yadav KK, Arora PS, Bar-Sagi D (2011) An orthosteric inhibitor of the Ras-Sos interaction. *Nat Chem Biol* 7(9):585–587.
- Wang D, Lu M, Arora PS (2008) Inhibition of HIV-1 fusion by hydrogen-bond-surrogate-based alpha helices. *Angew Chem Int Ed Engl* 47(10):1879–1882.
- Kung AL, et al. (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. *Cancer Cell* 6(1):33–43.
- Patgiri A, Menzenski MZ, Mahon AB, Arora PS (2010) Solid-phase synthesis of short α -helices stabilized by the hydrogen bond surrogate approach. *Nat Protoc* 5(11):1857–1865.
- Dial R, Sun ZY, Freedman SJ (2003) Three conformational states of the p300 CH1 domain define its functional properties. *Biochemistry* 42(33):9937–9945.
- De Guzman RN, Wojcik JM, Martinez-Yamout MA, Dyson HJ, Wright PE (2005) CBP/p300 TAZ1 domain forms a structured scaffold for ligand binding. *Biochemistry* 44(2):490–497.
- Vo N, Goodman RH (2001) CREB-binding protein and p300 in transcriptional regulation. *J Biol Chem* 276(17):13505–13508.
- Block KM, et al. (2009) Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidthiodiketopiperazine. *J Am Chem Soc* 131(50):18078–18088.
- Dubey R, et al. (2013) Suppression of tumor growth by designed dimeric epidthiodiketopiperazine targeting hypoxia-inducible transcription factor complex. *J Am Chem Soc* 135(11):4537–4549.
- Shibata T, Giaccia AJ, Brown JM (2000) Development of a hypoxia-responsive vector for tumor-specific gene therapy. *Gene Ther* 7(6):493–498.
- Fang Y, Sullivan R, Graham CH (2007) Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity. *Exp Cell Res* 313(5):867–877.
- Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A (2001) Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. *J Biol Chem* 276(12):9519–9525.
- Erler JT, et al. (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. *Nature* 440(7088):1222–1226.
- Cook KM, et al. (2009) Epidthiodiketopiperazines block the interaction between hypoxia-inducible factor-1 α (HIF-1 α) and p300 by a zinc ejection mechanism. *J Biol Chem* 284(39):26831–26838.
- Kushal S, Wang H, László CF, Szábo LZ, Olenyuk BZ (2011) Inhibition of hypoxia-inducible transcription factor complex with designed epipolythiodiketopiperazine. *Biopolymers* 95(1):8–16.
- Tyndall JD, Nall T, Fairlie DP (2005) Proteases universally recognize beta strands in their active sites. *Chem Rev* 105(3):973–999.
- James K, et al. (1999) Measuring response in solid tumors: Unidimensional versus bidimensional measurement. *J Natl Cancer Inst* 91(6):523–528.
- Pàez-Ribes M, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. *Cancer Cell* 15(3):220–231.
- Yang X, et al. (2010) Near IR heptamethine cyanine dye-mediated cancer imaging. *Clin Cancer Res* 16(10):2833–2844.
- Ravindranathan P, et al. (2013) Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. *Nat Commun* 4:1923.
- Koehler AN (2010) A complex task? Direct modulation of transcription factors with small molecules. *Curr Opin Chem Biol* 14(3):331–340.
- Lee LW, Mapp AK (2010) Transcriptional switches: Chemical approaches to gene regulation. *J Biol Chem* 285(15):11033–11038.
- Yang F, et al. (2013) Antitumor activity of a pyrrole-imidazole polyamide. *Proc Natl Acad Sci USA* 110(5):1863–1868.
- Muzikar KA, Nickols NG, Dervan PB (2009) Repression of DNA-binding dependent glucocorticoid receptor-mediated gene expression. *Proc Natl Acad Sci USA* 106(39):16598–16603.